Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

79.500
-0.400-0.50%
Volume:8.29M
Turnover:659.44M
Market Cap:137.93B
PE:-1.18K
High:80.950
Open:77.100
Low:77.100
Close:79.900
52wk High:109.100
52wk Low:34.650
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:0.87
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.068
ROE:8.43%
ROA:2.65%
PB:8.49
PE(LYR):-1,175.79
PS:10.72

Loading ...

JPMorgan Boosts Stake in Innovent Bio by Approximately 1.23 Million Shares at HK$78.70 Each

Stock News
·
Yesterday

Goldman Sachs Raises INNOVENT BIO's Profit Forecasts, Maintains Buy Rating with HK$102.85 Target

Stock News
·
Yesterday

Innovent Biologics (01801) Announces Monthly Return on Movements in Securities for January 2026

Bulletin Express
·
Feb 05

Innovent Bio Shares Slip Nearly 4% Following One-Time Channel Inventory Provision; Institutions Affirm Q4 Performance Meets Expectations

Stock News
·
Feb 05

Hong Kong Stock Announcement Highlights | Yum China's 2025 Operating Profit Rises 11% to $1.3 Billion

Stock News
·
Feb 04

INNOVENT BIO (01801) Reports Total Product Revenue of Approximately RMB 11.9 Billion in 2025, Maintaining Robust Growth of About 45% Year-on-Year

Stock News
·
Feb 04

Innovent Biologics (1801) Reports Strong 2025 Product Revenue Growth

Bulletin Express
·
Feb 04

Innovent Biologics - for the Full Year of 2025, the Total Product Revenue RMB11.9 Billion

THOMSON REUTERS
·
Feb 04

Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue

Reuters
·
Feb 04

JPMorgan Increases Stake in Innovent Bio (01801) by Approximately 199,000 Shares at HK$83.83 Per Share

Stock News
·
Feb 03

Novo Nordisk's China President Zhou to step down in March

Reuters
·
Jan 30

Valuation Ranges of Biopharma: Insights from Innovent Biologics, Hengrui Pharmaceuticals, and BeiGene

Deep News
·
Jan 30

Hong Kong Stock Movement | Innovent Biologics (01801) Rises Nearly 3% as IBI3003 Receives FDA Fast Track Designation for Multiple Myeloma Treatment

Stock News
·
Jan 28

FDA Grants Fast Track Designation to Innovent's IBI3003 for Relapsed or Refractory Multiple Myeloma

Reuters
·
Jan 27

Innovent Announces Ibi3003 (Gprc5d/Bcma/Cd3 Trispecific Antibody) Receives Fast Track Designation From the U.S. FDA for Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Jan 27

Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial

Reuters
·
Jan 09

Innovent's Partner Ollin Biosciences Announces Positive Topline Data With Superior Outcomes From a Randomized Head-to-Head Study of Ibi324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
Jan 09

JPMorgan Increases Stake in Innovent Biologics (01801) by Approximately 3.17 Million Shares at HK$78.45 Per Share

Stock News
·
Jan 08

Innovent Should Hold Own in Weight-Loss Drug Race Despite Intensifying Competition -- Market Talk

Dow Jones
·
Jan 06

Novo and Lilly cut prices of weight-loss drugs in China

Reuters
·
Dec 29, 2025